AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System

Rhea-AI Summary

AngioDynamics, Inc. (NASDAQ: ANGO) announced that it received 510(k) clearance from the FDA for the AlphaVac Mechanical Thrombectomy System, designed for non-surgical removal of thrombi or emboli. The commercial release is anticipated in the second half of 2021. Additionally, the Company will report its fourth quarter and fiscal year 2021 financial results on July 13, 2021, with a conference call scheduled at 8:00 a.m. ET, followed by a virtual Investor and Technology Day at 9:30 a.m. ET.

Positive

• FDA clearance for AlphaVac Mechanical Thrombectomy System enhances product portfolio.
• Anticipated commercial release could drive future revenue growth.

Negative

• None.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the AlphaVac Mechanical Thrombectomy System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the non-surgical removal of thrombi or emboli from the vasculature.

AngioDynamics continues to anticipate the commercial release of the AlphaVac System in the second half of calendar year 2021.

The Company will report financial results for the fourth quarter and fiscal year 2021 before the market open on Tuesday, July 13, 2021. The Company’s management will host a conference call at 8:00 a.m. ET to discuss the results.

Management will also host a virtual Investor and Technology Day following its earnings conference call at 9:30 a.m. ET that same day.

Further details, including registration, webcast, and dial-in information, will be provided at a later date.

About AngioDynamics, Inc.

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.

AngioDynamics and AlphaVac are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005400/en/

FAQ

What is the AlphaVac Mechanical Thrombectomy System by ANGO?

The AlphaVac Mechanical Thrombectomy System is an FDA-cleared device for the non-surgical removal of thrombi or emboli from the vasculature.

When will AngioDynamics report its financial results for Q4 2021?

AngioDynamics will report its fourth quarter and fiscal year 2021 financial results on July 13, 2021.

What time is the conference call for ANGO's financial results?

The conference call for AngioDynamics' financial results is scheduled at 8:00 a.m. ET on July 13, 2021.

When is the virtual Investor and Technology Day for ANGO?

The virtual Investor and Technology Day will take place at 9:30 a.m. ET on July 13, 2021, following the earnings conference call.

What does the FDA clearance mean for AngioDynamics and its stock ANGO?

The FDA clearance for the AlphaVac System is a significant step that may enhance AngioDynamics' market competitiveness and potentially increase stock value.